Catalyst Wire Dossier Catalyst Wire Dossier

HL1113R1

· Hanlim Pharm. Co., Ltd.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for HL1113R1, covering 2026-04-27 to 2026-04-27. Get the full timeline:

Most recent: Clinical Trial Update: Clinical Trial to Evaluate the Efficacy and Safety of Monotherapy Group of HL1113R1 or HL1113R2 Versus HL1113 (Fixed Dose Combination) in Patients With Essential Hypertension and Type II Diabetes Mellitus [Phase 3]

See pricing